Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rhea-AI Summary

Maze Therapeutics (Nasdaq: MAZE) announced that CEO Jason Coloma, Ph.D., will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Feb. 11, 2026 at 3:00 p.m. ET. A live webcast will be available in the Investors section of the Maze Therapeutics website and archived for 60 days.

Key Figures

Summit date: February 11, 2026 Presentation time: 3:00 p.m. ET Webcast archive period: 60 days

3 metrics

Summit date February 11, 2026 Date of Guggenheim Emerging Outlook: Biotech Summit 2026 presentation

Presentation time 3:00 p.m. ET Scheduled time for MAZE presentation at the summit

Webcast archive period 60 days Duration webcast will remain available after the presentation

Market Reality Check

Price: $48.14 Vol: Volume 741,130 is above t...

high vol

$48.14 Last Close

Volume Volume 741,130 is above the 20-day average of 432,136, indicating elevated interest ahead of the summit appearance. high

Technical Shares at $47.97 are trading above the 200-day MA of $23.78 and sit close to the $48.75 52-week high.

Peers on Argus

MAZE gained 3.09% while close peers showed mixed, mostly modest moves (e.g., ORI...

MAZE gained 3.09% while close peers showed mixed, mostly modest moves (e.g., ORIC -1.48%, ELVN -2.82%, WVE +1.11%), pointing to a stock-specific move rather than a broad biotech shift.

Common Catalyst Both MAZE and SION issued conference participation news tied to the Guggenheim Emerging Outlook: Biotech Summit 2026, but only MAZE shows a notable pre-news price gain.

Historical Context

5 past events · Latest: Jan 05 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Conference participation	Neutral	-2.9%	J.P. Morgan Healthcare Conference presentation and webcast details.
Nov 06	Earnings and pipeline	Neutral	-3.5%	Q3 2025 financials plus MZE782 Phase 1 data and 2026 trial plans.
Nov 06	Scientific data update	Positive	-2.1%	Additional MZE782 and MZE829 data presented at ASN Kidney Week.
Nov 04	Investor conferences	Neutral	-2.5%	Multiple November–December 2025 investor conference appearances.
Oct 06	Board leadership change	Positive	+1.5%	Appointment of Hervé Hoppenot as chairman and financing/milestone highlights.

Pattern Detected

Conference and scientific visibility updates have often coincided with modest negative or muted price reactions, with only the board chair appointment drawing a positive move.

Recent Company History

Over the last several months, MAZE has focused on visibility events and pipeline/financial updates. Conference participation notices on Nov 4, 2025 and Jan 5, 2026 were followed by –2.47% and –2.87% moves. Scientific and earnings updates on Nov 6, 2025 also saw modest declines despite pipeline progress. By contrast, the new chairman announcement on Oct 6, 2025 coincided with a +1.51% move, highlighting better reception for governance and financing milestones.

Market Pulse Summary

This announcement highlights Maze Therapeutics’ participation in a high-profile biotech investor sum...

Analysis

This announcement highlights Maze Therapeutics’ participation in a high-profile biotech investor summit on February 11, 2026, with a webcast available for 60 days. It fits a pattern of active conference engagement alongside prior scientific and financial updates. Investors tracking the story may focus on how management frames kidney and metabolic disease programs and whether any future events build on previously outlined 2026 clinical milestones.

Key Terms

small molecule, precision medicines, webcast

3 terms

small molecule medical

"developing small molecule precision medicines for patients with kidney"

A small molecule is a low-weight chemical compound that can enter cells easily and interact with specific proteins or biological pathways to change how they work, much like a small key fitting into a lock. Investors care because small molecules are a common and often faster route to develop medicines, can be manufactured at scale, and may offer clearer regulatory and commercial paths compared with larger biologic therapies, affecting potential costs, timelines and returns.

precision medicines medical

"developing small molecule precision medicines for patients with kidney"

Precision medicines are treatments designed to work for specific groups of patients identified by genetic, biological, or lifestyle characteristics, rather than a one-size-fits-all drug. They matter to investors because these therapies can be more effective and command premium pricing in smaller, well-defined markets—offering higher potential returns if successful but also concentrated development and regulatory risk, like betting on a tailored suit that fits only certain people.

webcast technical

"A live webcast of the event will be available in the Investors section"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 3:00 p.m. ET.

A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentation.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases, including obesity. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow the company on LinkedIn and X.

IR/Corporate Contact:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

FAQ

When will Maze Therapeutics (MAZE) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?

Maze Therapeutics will present on Wednesday, February 11, 2026 at 3:00 p.m. ET. According to the company, CEO Jason Coloma, Ph.D., will deliver the presentation and participate in the summit session scheduled at that time.

How can investors watch the Maze Therapeutics (MAZE) presentation on February 11, 2026?

Investors can watch via a live webcast on the company's investor website at www.mazetx.com. According to the company, the webcast will be available live and an archived recording will remain accessible for 60 days after the presentation.

Who will represent Maze Therapeutics (MAZE) at the Guggenheim Biotech Summit 2026 presentation?

Jason Coloma, Ph.D., chief executive officer, will represent Maze Therapeutics at the presentation. According to the company, Dr. Coloma will present on the scheduled Feb. 11, 2026 session at 3:00 p.m. ET.

Will the Maze Therapeutics (MAZE) webcast be available after the Guggenheim summit presentation?

Yes, the webcast will be archived for 60 days following the presentation. According to the company, the archived recording will remain accessible in the Investors section of the Maze Therapeutics website for that 60-day period.

Where on Maze Therapeutics' site can I find the Guggenheim summit webcast and archive for MAZE?

The webcast and archive will be posted in the Investors section of Maze Therapeutics' website at www.mazetx.com. According to the company, the live stream will be hosted there and the recording archived for 60 days.